Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Sends Expression System for Beta Testing; Announces Exec s Departure

NEW YORK, March 15 – Nanogen said Thursday it had shipped a new system designed for targeted gene expression applications for beta testing at two undisclosed US institutions and one in Europe.

Nanogen plans to use the results of the tests to develop new applications for detecting gene expression. Currently the company’s NanoChip system is primarily used do detect and analyze SNPs, short tandem repeats, and mutations.

Nanogen said that its system would differ from most commercial gene expression techniques by allowing researchers to get quantitative, reproducible assays with a known set of genes.

“These scientists will be looking for the capability to perform time-series studies with multiple samples on a single chip or across multiple chips,” Nanogen said in a statement.

Nanogen also said that it had upgraded the loader of its NanoChip system so that it can handle either a 384 or a 96 well plate. 

In addition, Nanogen announced that George Bers, vice president of Business Development, left the company to take a job in the Bioresearch Division of Beckman Coulter.

Nanogen did not announce a replacement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.